Page 55 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Cancer Chemother Pharmacol. 2015;75(4):763-772.
46. Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism
in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11(16):5886-5892.
47. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other 3
fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-
analysis. J Clin Oncol. 2014;32(10):1031-1039.
48. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain
DPD deficiency in cancer patients. Pharmacogenetics. 2000;10(3):217-223.
49. Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiader CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine
toxicity. International Journal of Cancer. 2015;136(3):730-739.
50. Sistonen J, Buchel B, Froehlich TK, et al. Predicting 5-fluorouracil toxicity: DPD genotype and
5,6-dihydrouracil:uracil ratio. Pharmacogenomics. 2014;15(13):1653-1666.
51. Gamelin E, Boissdron-Celle M, Guerin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining
optimal 5-FU dosage. J Clin Oncol. 1999;17(4):1105-1110.
52. Jiang H, Lu J, Jiang J, Hu P. Important role of the dihydrouracil/uracil ratio in marked interpatient
variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol.
2004;44(11):1260-1272.
53. Wettergren Y, Carlsson G, Odin E, Gustavsson B. Pretherapeutic uracil and dihydrouracil levels
of colorectal cancer patients are associated with sex and toxic side effects during adjuvant
5-fluorouracil-based chemotherapy. Cancer. 2012;118(11):2935-2943.
54. Kristensen MH, Pedersen P, Mejer J. The value of dihydrouracil/uracil plasma ratios in predicting
5-fluorouracilrelated toxicity in colorectal cancer patients. J Int Med Res. 2010;38(4):1313-1323.
55. Ben FR, Gross E, Ben AS, Hassine H, Saguem S. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal
cancer patients treated with 5-fluorouracil. Pathol Biol (Paris). 2009;57(6):470-476.
56. Largiader CR, Amstutz U, Froehlich TK, et al. The dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity: a classic reborn? . Paper presented at: Cold Spring Harbor, New York, USA, 17 November-21 November 2010Presented at: 2010 meeting on
Pharmacogenomics and Personalized Medicine. .
57. Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a
predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415-
1424.
58. Jacobs BAW, Rosing H, de Vries N, et al. Development and validation of a rapid and sensitive
UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm
Biomed Anal. 2016;126:75-82.
59. Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of concentration and
functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem. 2004;50(9):1623-1633.
DPYD gene activity score
53